COMT

Across TCGA pan-cancer cohorts, COMT mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated COMT data layer compared with 30 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher COMT mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated COMT expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where COMT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.605	1.000	.001	27	view →
PDAC	OS	Quartile	II,III,IV	0.613	0.300	.003	11	view →
UCEC	OS	Tertile	All	1.000	0.908	.041	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

COMT–CCRCC (OS)

Open the CCRCC breakdown →